This was a large observational study using national prescription and health registry data of postmenopausal women (hundreds of thousands) to examine links between menopausal hormone therapy (MHT) and later diagnosis of Alzheimer’s disease and related dementias. Researchers compared women who used estrogen-only MHT, estrogen plus progestogen, or no MHT. They tracked type of hormone, route (oral vs transdermal), dose, timing relative to menopause, and duration of use. The primary endpoint was new diagnosis of Alzheimer’s disease or other dementias over long-term follow-up.
Women who used estrogen-only MHT, especially when started before age 60 or within about 10 years of menopause, had a statistically significant lower risk of Alzheimer’s disease and other dementias than women who did not use MHT. Longer duration of estrogen-only therapy tended to be associated with stronger risk reduction. Findings for combined estrogen–progestogen therapy were more mixed, with some regimens suggesting modest benefit and others closer to neutral, depending on timing, dose, and formulation. Because this was not a randomized trial, researchers reported associations rather than proof that MHT directly prevents dementia.
This was an observational registry study, so it can show associations but cannot prove that estrogen therapy itself prevents Alzheimer’s disease or dementia. Important confounders—such as education level, lifestyle, cardiovascular risk management, diet, and detailed family history—may not have been fully captured or adjusted for. The population may be largely from one country and health system, limiting how well the results apply to more diverse groups. Formulations, doses, and routes of MHT used in this cohort may not match current practice everywhere, and long-term safety trade-offs (breast cancer, blood clots, stroke) were not the main focus here; uncertainties remain about the safest combinations and durations for different risk profiles.
This study adds to growing evidence that timing and type of menopausal hormone therapy may influence long-term brain health, supporting a possible “critical window” near menopause where estrogen exposure could be more protective. The registry design offers large numbers and real-world data, but also brings substantial confounding: women who choose MHT may be healthier, more health-literate, and differently screened than non-users, which can bias results. These findings partially contrast with older trials like the Women’s Health Initiative Memory Study, which suggested increased dementia risk with later-initiated combined MHT in older women, highlighting that age at start and formulation matter. Clinically, this study nudges the conversation away from automatic fear of estrogen for the brain, toward individualized risk–benefit discussions that include cognitive outcomes, but it does not overturn the need for caution with breast cancer, VTE, and other known risks.
If you are near menopause and struggling with symptoms, this research suggests that appropriately timed estrogen therapy might support long-term brain health, but it is not a guarantee and is not right for everyone. For women with a uterus, progestogen is still needed alongside estrogen to protect the uterine lining; the brain effects of different progestogens (e.g., micronized progesterone vs certain synthetic progestins) may differ and should be discussed with a clinician. Restorative care will also look beyond hormones alone: supporting sleep, insulin sensitivity, blood pressure, inflammation, and cycle/hormone patterns in the years leading up to menopause, because these factors also influence dementia risk. Any decision about MHT should be made with a clinician who can review your personal risks (breast, clotting, stroke, cardiovascular disease, migraine, family history) and align treatment with your long-term health goals.
This study looked at many women who used hormone therapy around menopause and followed them to see who later developed Alzheimer’s disease or similar memory problems. Women who used estrogen-only therapy, especially when started closer to menopause, seemed less likely to develop these brain conditions later in life. This does not prove that estrogen “protects” the brain for every woman, and it does not remove other risks of hormone therapy, like blood clots or certain cancers. For someone on a fertility or hormone-health journey, this points to the importance of understanding your hormone patterns over time, addressing root causes like inflammation, blood sugar issues, and sleep problems, and then deciding with a clinician if hormone therapy near menopause fits safely into your long-term plan.
Data support a timing hypothesis: estrogen-only MHT initiated before ~60 years or within ~10 years of menopause appears associated with reduced risk of Alzheimer’s disease and related dementias, with a dose–duration trend. Combined regimens show more heterogeneous effects; outcomes may differ by progestogen type (micronized progesterone vs synthetic progestins), route (oral vs transdermal), and regimen (continuous vs cyclic), though this study’s granularity may be limited. For restorative practice, consider integrating pre-menopausal risk stratification: cognitive family history, APOE status where appropriate, metabolic and vascular markers (A1c, fasting insulin, lipids, hs-CRP, homocysteine, BP), and perimenopausal cycle/bleeding patterns before initiating MHT. When MHT is considered, favor physiologic, lowest-effective dosing, transdermal estradiol where thrombotic risk is a concern, and body-identical progesterone for endometrial protection and potential neurosteroid benefits, recognizing that high-quality RCT data on dementia endpoints remain limited. Continue to frame MHT as one tool among many (sleep, exercise, nutrition, vascular risk control, cognitive engagement) rather than a standalone dementia-prevention strategy, and discuss the persistent uncertainties and trade-offs transparently.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.